Theravance touts mid-stage asthma drug results; Eisai opens $100M facility in RTP;

 @FierceBiotech: Roche, Biogen shutter blockbuster ocrelizumab arthritis program. Article | Follow @FierceBiotech

 @JohnCFierce: NicOx is trying to make it look like naproxcinod has a good future. It isn't working. Article | Follow @JohnCFierce

> Theravance says that a mid-stage trial of its new asthma therapy demonstrated that it was safe. The trial of vilanterol trifenatate, coded GW642444M, was undertaken by GlaxoSmithKline. Story

> Japan's Eisai has opened its $100 million manufacturing facility in Research Triangle Park. Report

> Genzyme spent $712,000 lobbying the government in the first quarter. One big win: 12 years of market exclusivity for biologics. But Genzyme also got hit with a painful FDA review of its manufacturing operations. Story

> The FDA approved Allergan's Zymaxid (gatifloxacin ophthalmic solution) 0.5 percent, a topical fluoroquinolone anti-infective for the treatment of bacterial conjunctivitis. Release

> Members of the city's legislative delegation are urging UMass Dartmouth to consider siting its multimillion-dollar biomanufacturing facility in New Bedford now that the project's intended site in Fall River is being considered for casino gaming. Report

And Finally... Shyness can influence the quality of an ongoing relationship--even one as important as marriage--according to a study in Personality and Social Psychology Bulletin. Report

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.